|10/19/2020||Orion's statutory co-operation negotiations completed regarding the Research & Development function|
|10/6/2020||Orion publishes Interim Report for January-September 2020 on Wednesday 21 October 2020|
|9/10/2020||Orion is planning to renew its R&D strategy and organisation|
|9/10/2020||New England Journal of Medicine publishes final overall survival data for darolutamide showing treatment significantly extends life in men with non-metastatic prostate cancer|
Orion published Interim Report for January-September 2020 on Wednesday, 21 October 2020. The report, related presentation material and a link to live webcast are available here.
The 2020 Annual General Meeting of Orion was held on Wednesday, 6 May 2020. The decisions and related material are available here.
|10/21/2020||Composition of the Nomination Committee of Orion Corporation|
|10/21/2020||Orion Group Interim Report 1-9/2020|
|10/19/2020||Orion upgrades full-year outlook for 2020|
|10/19/2020||120,939 Orion Corporation A shares converted into B shares|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.